Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright

Annovis Bio (NYSE:ANVS) had its target price decreased by HC Wainwright from $30.00 to $12.00 in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Annovis Bio’s Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.52) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.66) EPS.

ANVS has been the topic of several other research reports. D. Boral Capital reissued a “hold” rating on shares of Annovis Bio in a report on Monday, February 10th. Canaccord Genuity Group dropped their price objective on Annovis Bio from $26.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $30.25.

Annovis Bio Stock Performance

NYSE ANVS opened at $2.81 on Monday. Annovis Bio has a fifty-two week low of $1.11 and a fifty-two week high of $17.88. The stock has a 50-day simple moving average of $1.83 and a two-hundred day simple moving average of $3.10. The firm has a market capitalization of $54.66 million, a P/E ratio of -0.63 and a beta of 1.62.

Annovis Bio (NYSE:ANVS) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.15. As a group, analysts forecast that Annovis Bio will post -2.19 earnings per share for the current year.

Hedge Funds Weigh In On Annovis Bio

Several large investors have recently modified their holdings of ANVS. Lokken Investment Group LLC increased its stake in shares of Annovis Bio by 60.3% in the first quarter. Lokken Investment Group LLC now owns 29,235 shares of the company’s stock valued at $44,000 after purchasing an additional 11,000 shares during the period. Two Sigma Investments LP acquired a new position in Annovis Bio in the 4th quarter worth approximately $55,000. Warberg Asset Management LLC acquired a new position in Annovis Bio in the 1st quarter worth approximately $58,000. XTX Topco Ltd purchased a new stake in Annovis Bio in the 4th quarter worth approximately $59,000. Finally, Atria Wealth Solutions Inc. bought a new position in shares of Annovis Bio during the 4th quarter valued at $65,000. Institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.